Ballentine Partners, LLC Dexcom Inc Transaction History

Ballentine Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	SELL	$110.31 - $140.45 $28,790 - $36,657	-261 Reduced 10.37%	2,256 $255,000
Q1 2024 Apr 11, 2024	BUY	$114.22 - $140.1 $30,382 - $37,266	266 Added 11.82%	2,517 $349,000
Q4 2023 Jan 23, 2024	SELL	$75.49 - $124.16 $68,091 - $111,992	-902 Reduced 28.61%	2,251 $279,000
Q3 2023 Oct 19, 2023	BUY	$86.06 - $137.93 $59,725 - $95,723	694 Added 28.22%	3,153 $294,000
Q2 2023 Jul 26, 2023	SELL	$112.47 - $130.98 $86,152 - $100,330	-766 Reduced 23.75%	2,459 $316,000
Q1 2023 Apr 27, 2023	BUY	$104.0 - $122.92 $97,760 - $115,544	940 Added 41.14%	3,225 $374,000
Q4 2022 Jan 27, 2023	BUY	$84.98 - $122.67 $194,179 - $280,300	2,285 New	2,285 $0

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31.1B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Ballentine Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Ballentine Partners, LLC with notifications on news.